Design, Synthesis, Cytotoxicity Assessment, and Molecular Docking of Novel Triazolopyrimidines as Potent Cyclin‐Dependent Kinase 4 Inhibitors
Authors:
Open Access
- 2 November 2025
- journal article
- Published by Wiley in ChemistryOpen
- Vol. 15 (4) , e202500324
Abstract
Cyclin‐dependent kinase 4 (CDK4) plays a pivotal role in cell cycle regulation and is a well‐established target in cancer therapy. Triazolopyrimidines, as bioactive heterocyclic compounds, represent a promising scaffold for the development of novel anticancer agents. Herein, a new series of 1,5‐dihydro‐[1,2,4]triazolo[4,3‐a]pyrimidine derivatives ( 5a–g ) is synthesized via multistep reactions involving 6‐methyl‐4‐phenyl‐2‐thioxo‐1,2,3,4‐tetrahydropyrimidin‐5‐yl propionate and hydrazonoyl halides. Structural confirmation is achieved through infrared spectroscopy, 1 H nuclear magnetic resonance, mass spectrometry, and elemental analysis, and further supported by alternative synthetic approaches. Molecular docking studies targeting the CDK4/cyclin D1 complex (PDB ID: 2W9Z) reveal favorable binding interactions, particularly for compounds 5c and 5d , with binding energies of −7.34 and −7.25 kcal/mol, respectively. In vitro cytotoxicity assays against HepG2 liver cancer cells show that compounds 5c, 5d, and 5f exhibit potent activity, with IC 50 values of 4.38, 3.96, and 3.84 µM, respectively, comparable to doxorubicin (3.43 µM). A similar trend is observed in MCF‐7 breast cancer cells, where 5c , 5d , and 5f again demonstrate strong antiproliferative effects with IC 50 values of 4.12, 3.87, and 3.95 µM, respectively, close to doxorubicin (3.25 µM). The absorption, distribution, metabolism, excretion, and toxicity profile indicates excellent absorption, moderate distribution, low toxicity, and favorable drug‐likeness. These findings highlight the potential of the synthesized triazolopyrimidine derivatives as promising leads for CDK4‐targeted anticancer drug development.Keywords
This publication has 66 references indexed in Scilit:
- Docking and simulation studies on cyclin D/CDK4 complex for targeting cell cycle arrest in cancer using flavanone and its congenerJournal of Molecular Modeling, 2023
- 2D-QSAR modeling and two-fold classification of 1,2,4-triazole derivatives for antitubercular potency against the dormant stage of Mycobacterium tuberculosisMolecular Diversity, 2021
- Biological activities of [1,2,4]triazolo[1,5-a]pyrimidines and analogsMedicinal Chemistry Research, 2020
- Efficient Synthesis of Some New 1,3,4‐Thiadiazoles and 1,2,4‐Triazoles Linked to Pyrazolylcoumarin Ring System as Potent 5α‐Reductase InhibitorsJournal of Heterocyclic Chemistry, 2019
- Synthesis of some new Pyridine‐based Heterocyclic Compounds with Anticipated Antitumor ActivityJournal of Heterocyclic Chemistry, 2018
- Prediction and Optimization of Pharmacokinetic and Toxicity Properties of the Ligand2018
- Synthesis and Antimicrobial Activity of Novel Azolopyrimidines and Pyrido‐Triazolo‐Pyrimidinones Incorporating Pyrazole MoietyJournal of Heterocyclic Chemistry, 2017
- Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structuresProteins: Structure, Function, and Bioinformatics, 2009
- Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: Protein structure-guided design and SARBioorganic & Medicinal Chemistry Letters, 2006
- Pharmacokinetics and its role in small molecule drug discovery researchMedicinal Research Reviews, 2001